Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study by Ndege, Robert et al.
STUDY PROTOCOL Open Access
Ultrasound in managing extrapulmonary
tuberculosis: a randomized controlled two-
center study
Robert Ndege1,2*†, Omary Ngome1,3†, Farida Bani1,2, Yvan Temba1,3, Herieth Wilson1,2, Fiona Vanobberghen4,5,
Jerry Hella1, Winfrid Gingo2, Mohamed Sasamalo1, Dorcas Mnzava1, Namvua Kimera1, Helen Hiza1, John Wigayi1,
Herry Mapesi1, Irene B. Kato3, Francis Mhimbira1, Klaus Reither4,5, Manuel Battegay6,5, Daniel H. Paris4,5,
Maja Weisser1,5,6 and Martin Rohacek1,2,4,5*
Abstract
Background: Patients with clinically suspected tuberculosis are often treated empirically, as diagnosis - especially of
extrapulmonary tuberculosis - remains challenging. This leads to an overtreatment of tuberculosis and to
underdiagnosis of possible differential diagnoses.
Methods: This open-label, parallel-group, superiority randomized controlled trial is done in a rural and an urban
center in Tanzania. HIV-positive and -negative adults (≥18 years) with clinically suspected extrapulmonary
tuberculosis are randomized in a 1:1 ratio to an intervention- or control group, stratified by center and HIV status.
The intervention consists of a management algorithm including extended focused assessment of sonography for
HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests. Treatment with anti-
tuberculosis drugs is started, if eFASH is positive, chest X-ray suggests tuberculosis, or a microbiological result is
positive for tuberculosis. Patients in the control group are managed according national guidelines. Treatment is
started if microbiology is positive or empirically according to the treating physician. The primary outcome is the
proportion of correctly managed patients at 6 months (i.e patients who were treated with anti-tuberculosis
treatment and had definite or probable tuberculosis, and patients who were not treated with anti-tuberculosis
treatment and did not have tuberculosis). Secondary outcomes are the proportion of symptom-free patients at two
and 6 months, and time to death. The sample size is 650 patients.
Discussion: This study will determine, whether ultrasound in combination with other tests can increase the
proportion of correctly managed patients with clinically suspected extrapulmonary tuberculosis, thus reducing
overtreatment with anti-tuberculosis drugs.
Trial registration: PACTR, Registration number: PACTR201712002829221, registered December 1st 2017.
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Background
In resource-limited settings with a high tuberculosis
prevalence, almost half of patients are treated empirically
with anti-tuberculosis drugs upon clinical suspicion only
[1–3]. Besides lack of available tests, this is mainly due
to the poor sensitivity of microbiological tests, especially
in patients co-infected with human immunodeficiency
virus (HIV) or in those with suspected extrapulmonary
tuberculosis [4, 5]. The decision to treat tuberculosis
based on clinical signs and symptoms only has a low ac-
curacy for culture-confirmed tuberculosis, and 30–60%
of these decisions lead to false treatment [1, 3, 6]. The
consequence is, that patients are unnecessarily exposed
to potentially toxic drugs for long time periods, and the
diagnosis of their real disease such as other infections,
cancer or heart failure is delayed, or missed. Additional
diagnostic methods are therefore needed to distinguish
tuberculosis from other diseases with similar symptoms.
Ultrasound is a widely available diagnostic tool, which
is used in various medical fields. Focused Assessment
with Sonography for HIV and Tuberculosis (FASH) is a
useful tool to detect signs of extrapulmonary tubercu-
losis, namely pleural and pericardial effusion, enlarged
abdominal lymph nodes, hypoechogenic lesions in the
spleen and the liver, ascites and thickening of the bowel
wall [7]. FASH can be performed as a point of care bed-
side test and can be taught to personnel with little or no
previous experience in ultrasonography [8]. In our ob-
servational study from rural Tanzania including 191
HIV-positive and -negative patients with suspected pul-
monary or extrapulmonary tuberculosis, abnormal chest
X-ray, presence of ≥1 FASH-sign, and elevated body
temperature were independently associated with con-
firmed tuberculosis. A combination of ≥1 FASH sign,
abnormal chest X-ray, and temperature ≥ 37.5 °C had a
high (99.1%) sensitivity but a low (35.2%) specificity for
confirmed tuberculosis. We concluded that ultrasound
might be useful to exclude tuberculosis, in combination
with other tests [9]. In a recent Cochrane metanalysis in-
cluding HIV-positive adults, FASH signs predicted tu-
berculosis with a moderate diagnostic performance only.
The authors also concluded that ultrasound results
should be considered in combination with other tests,
such as chest X-ray and Xpert MTB/RIF® only [10]. No
randomized controlled trial evaluating sonography for
the diagnosis of tuberculosis has been done yet.
With our randomized controlled trial, we aim to deter-
mine whether sonography, added to chest X-ray and
microbiological tests, has an impact on the proportion
of correctly managed patients with suspected extrapul-
monary tuberculosis, and on morbidity and mortality.
We have added the sonography of axillary and cervical
lymph nodes, of the chest, and of the vena cava to the
FASH protocol, and call it extended FASH (eFASH). We
hypothesize that the proportion of correctly managed
patients after 6 months will be higher in the intervention
group versus the control group.
Methods
Study design and setting
This is a two-center, open-label, parallel-group, super-
iority randomized controlled trial. Patients are consecu-
tively recruited at St. Francis Referral Hospital, Ifakara
and Mwananyamala Regional Referral Hospital, Dar es
Salaam, United Republic of Tanzania.
St. Francis Referral Hospital serves a rural population
of about 1 million people as a referral center. It includes
the Chronic Diseases Clinic of Ifakara (CDCI), which
cares for over 4000 people living with HIV [11, 12] and/
or tuberculosis [13]. Mwananyamala Regional Referral
Hospital serves an urban population of Dar es Salaam
and is a referral center for tuberculosis within the
Kinondoni district. The planned study period is 2 years,
including 6 months of follow-up.
Patients
All HIV-positive and -negative adults aged ≥18 years
presenting to any department of the St. Francis Referral
Hospital, CDCI or Mwananyamala Regional Referral
Hospital are screened by trained study personnel. Eli-
gible patients are those fulfilling clinical screening cri-
teria for extrapulmonary tuberculosis, with or without
concomitant signs of pulmonary tuberculosis (Table 1).
Study procedures intervention group and control group
Before randomization, all eligible and consenting pa-
tients receive a clinical evaluation including an interview
with a systematic assessment of symptoms. Physical
examination including measuring body weight and
height, blood pressure, heart rate, chest and abdominal
examination, and palpation of lymph nodes is done by
the study physician. All patients receive a chest X-ray,
an HIV test if the HIV status is not documented and
blood tests for hemoglobin, creatinine, and alanine ami-
notransferase. Microbiological analyses are performed as
follows: If a patient can produce sputum, conventional
Xpert MTB/RIF® (Cefeid, Sunnyvale, CA) is done. We
decided to use the conventional Xpert in sputum be-
cause the Xpert MTB/RIF Ultra® assay has a lower speci-
ficity in sputum, and might generate false positive
results [14]. Additionally, sputum samples are sent for
solid culture after adding cetylpyridinium chloride and
N-acetyl-l-cysteine-sodium hydroxide and are then inoc-
ulated on Löwenstein-Jensen medium [15]. For all pa-
tients, urine samples are collected and Xpert MTB/RIF
Ultra® assay is used [16, 17].
Patients allocated to the intervention group receive
additionally an eFASH examination. Anti-tuberculosis
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management and treatment is done according to an al-
gorithm (see Fig. 1). Patients allocated to the control
group are treated according national guidelines [18].
eFASH consists of sonographic evaluation of the
following:
 Original FASH signs: Pleural or pericardial effusion,
hypoechogenic lesions in spleen and liver, abdominal
lymphnodes > 1.5 cm, ascites, bowel wall thickening
 Extended signs: Diameter of the vena cava in order
to detect signs for heart failure; axillary, nuchal and
cervical lymph nodes > 1.5 cm; and B-lines and
echogenic bright granular artefacts in the subpleural
area in chest sonography. This is done by multiple
scans of the main bilateral chest areas (anterior su-
perior, lateral, posterior superior, posterior inferior
of the left and right chest) [19].
eFASH is performed by two trained study doctors in
patients in the intervention group only, before availabil-
ity of microbiological results. All sonographical investi-
gations are reviewed by an independent board-certified
sonographer with a minimum experience of 5 years after
the examination. This review will not influence the pa-
tient management, but it will be included in the final in-
terpretation of the data. All sonographical examinations
are done with a Sonobook 9 ultrasound machine (Chi-
son, Jiangsu, China). In case of pleural fluid or ascites,
fluid is taped and analysed using Xpert MTB/RIF Ultra®
assay, liquid culture, and adenosine deaminase (ADA;
Diazyme, Poway, USA). For liquid culture, bacteria
growth indicator tube (MGIT), with a BACTEC 960
Instrument (BD Microbiology Systems, Sparks, MD) is
used. In case of meningitis, lumbar puncture is per-
formed and cerebrospinal fluid analysed with Xpert
MTB/RIF Ultra® assay and liquid culture. In case of nu-
chal, cervical, or axillary lymphadenopathy, fine-needle
aspiration biopsy (FNAB) is done for Ziehl-Neelsen
stain, Giemsa- and Papanicolaou- stain for cytomorphol-
ogy, and liquid culture. If liquid material is aspirated
from a lymphnode, Xpert MTB/RIF Ultra® assay and cul-
ture is done. Patients with pericardial tamponade are re-
ferred for pericardiocentesis. Urine samples of 200 μl are
frozen at − 80 °C in order to evaluate the novel lipoarabi-
nomannan point of care test (FujiLAM) [20]. This will
not affect the outcomes of this study.
In the intervention group, anti-tuberculosis treatment
is started if any of the following is present: positive
eFASH, chest x-ray with typical signs for tuberculosis, or
positive microbiology from any site (Table 2). Anti-
tuberculosis treatment is withheld and other causes than
tuberculosis are considered if all microbiological tests
are negative for Mycobacterium tuberculosis; eFASH
does not show signs for extrapulmonary tuberculosis
and no cavernous lesion, upper-lobe infiltrate or miliary
pattern on the chest x-ray are seen. If the vena cava is
dilated > 2 cm and collapsing less than 50% during in-
spiration and no eFASH signs are present, heart failure
is considered. Presence of ascites with no other eFASH
signs points at pelvic inflammatory disease (PID) in fe-
males, liver cirrhosis, nephrotic syndrome, heart failure,
or at malignancy. Thickened ileum wall with loss of wall
architecture and no other eFASH signs points at bacter-
ial ileitis or Morbus Crohn. In case of ascites with
Table 1 Eligibility criteria
Inclusion
criteria
- Adult (≥18 years)
- Documented HIV status (HIV- positive and HIV- negative)
- Suspected extrapulmonary tuberculosis*:
presence of ≥1 sign or symptom of the following:
• Fever of any duration,
• Night sweat during 3 weeks within the last 4 weeks
• Weight loss
AND
presence of ≥1 sign or symptom of the following:
• Nuchal, cervical, axillary or generalized lymphadenopathy
• Abdominal pain or ascites
• Neurological symptoms (reduced consciousness, confusion, stiff neck, focal signs, persisting headache)
• Presence of severe anaemia (hemoglobin < 8 g/dl) in an HIV infected patient under antiretroviral treatment
• Local pain and spinal deformity, or arthritis suggesting spinal or osteoarticular tuberculosis
• Painless hematuria or sterile pyuria, scrotal nodules or epididymal Hardening, or salpingitis suggesting urogenital tuberculosis
• Chest x-ray with signs of miliary pattern, pleural effusion or suspected pericardial effusion
AND
No other obvious explanation for these signs
* with or without concomitant signs of pulmonary tuberculosis (i.e cough or chest x-ray with upper lobe infiltrate, cavernous lesion)
Exclusion
criteria
- Pregnancy
- Patients already on anti-tuberculosis treatment
- Refusal to participate or sign informed consent
- Not available for follow-up visits
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Fig. 1 Algorithm for management of intervention group and control group. LN: lymph node; TB: Tuberculosis; eFASH: Extended Focused
Assessment with Sonography for HIV and Tuberculosis; PE: pericardial effusion. † anti-tuberculosis treatment is started in case of a positive
microbiological result
Table 2 Criteria for starting anti-tuberculous treatment in the intervention group
Positive eFASH Multiple hypoechogenic lesions in the spleen or liver
Pericardial effusion and no other clinical explanation
Pleural effusion and no clinical or sonographic sign for heart failure (i.e normal V cava)
Subpleural echogenic granular artefacts and B-lines
abdominal, axillary, nuchal or cervical lymphnodes > 1.5 cm and no other clinical explanation for it
Thickened ileum wall (> 4 mm) and loss of wall architecture and at least one another eFASH sign
Ascites and at least one another eFASH sign
Chest X-ray with typical signs for
tuberculosis
Cavernous lesion, upper-lobe infiltrate or miliary pattern
Positive microbiological result from
any site
Positive Xpert MTB/RIF® assay and/or culture in sputum, pleural fluid, ascites, cerebrospinal fluid, or urine;
Adenosine deaminase (ADA) ≥40 U/ml in pleural fluid, [21], ADA≥ 35 U/ml in ascetic fluid [22], or ADA ≥35 U/
ml in pericardial fluid [5];
Positive fine needle aspiration result of lymph nodes (Xpert MTB/RIF® assay, culture, cytomorphology,
identification of acid fast bacilli)
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otherwise negative eFASH, a full abdominal sonography
to look for these diseases is done (Fig. 1).
Patients allocated to the control group are diagnosed
according to national guidelines [18] and the decision of
the treating physician. Patients receive empirical treat-
ment according to the discretion of the treating phys-
ician (Fig. 1). The treating physician of a control group
patient is allowed to use ultrasound for puncturing
pleural -or pericardial effusion, ascites, or lymph nodes,
or in case of a serious acute problem during follow-up
(e.g. suspected urolithiasis, cholecystitis, intestinal ob-
struction, perforation, appendicitis, or ruptured ectopic
pregnancy). All patients who receive anti-TB treatment
are routinely supervised by the treating Tuberculosis
clinics of both sites by drug tablet return checking
(weekly visits as per governmental guidelines, which can
be also in a peripheral dispensary).
Follow-up
In both groups, follow-up visits take place at two and
6 months after enrollment. Follow up visits include
physical examination, and eFASH in the intervention
group. If anti-tuberculosis treatment is not administered
at enrollment, additional follow-up visits are done at two
and 4 weeks. Transportation costs for study visits is paid
by the study budget. If a patient misses an appointment,
he or she will receive a phone call from the study team.
If a patient is not reachable by phone, he or she is
sought by an established collaboration with community
health care workers or by physical tracking to the pa-
tients home by motorbike.
Outcomes
The primary outcome is the proportion of correctly
managed patients at 6 months. Secondary outcomes are
the proportion of patients without symptoms at two and
6 months, and time to death. Other outcomes of interest
are the proportions of patients with microbiologically-
proven tuberculosis; with probable tuberculosis; with no
tuberculosis; with a diagnosis other than tuberculosis;
and receiving an invasive procedure. Safety outcomes
are the occurrence of pneumothorax, major bleeding,
and post-expansion pulmonary edema after interven-
tions such as pleural tapping, ascites puncture or fine-
needle aspiration.
Definitions
A patient is defined as having definite tuberculosis if any
of the microbiological tests is positive (Xpert TB/RIF®,
Xpert Ultra TB/RIF®, culture, acid fast bacilli in fine-
needle aspiration from lymphnodes, adenosine deami-
nase (ADA) ≥ 40 U/ml in pleural fluid [21], ADA ≥ 35 U/
ml in ascetic fluid [22], or ADA ≥ 35 U/ml in pericardial
fluid [5].
A patient is defined as having probable tuberculosis if
all microbiological tests are negative, and clinical, radio-
logical and sonographic (in the intervention group) signs
improve, and body weight is stable or increases after
2 months of anti-tuberculosis treatment. A patient is de-
fined not to have tuberculosis if all microbiological tests
were negative, and (a) clinical signs, symptoms and
radiological signs (and in patients in the intervention
group sonographic signs) improved, and body weight in-
creased, without start of anti-tuberculosis treatment or
(b) a diagnosis other than tuberculosis was found
explaining the symptoms in a patient with or without
anti-tuberculosis treatment.
A correctly managed patient is defined as one who
had definite or probable tuberculosis and was treated
with anti-tuberculosis treatment; or a patient who did
not have tuberculosis and was not treated with anti-
tuberculosis treatment.
Timeline
Recruitment started September 23rd 2018 and was ini-
tially planned until the end of February 2020 with a
follow-up until August 2020 (Table S1). Due to initial
slow recruitment, we planned a prolongation of recruit-
ment until June 2020 and of follow-up until December
2020. However, due to the SARS-CoV-2 pandemic, re-
cruitment had to be paused on March 30th 2020, based
on the recommendation of the National Institute for
Medical Research, Tanzania. Until March 30th 2020, a
total of 538 patients were included. To date, it is not
possible to determine the date when recruitment will be
resumed. Therefore, the study period will be prolonged
again by the time that recruitment was paused.
Recruitment
Patients are recruited in the emergency department, the
outpatient clinics, and the wards of the St Francis Refer-
ral Hospital, Ifakara, and at the Chronic Disease Clinic
Ifakara, and at the wards and outpatient clinics of the
Mwanyamamala Regional Hospital, Dar es salaam, were
tuberculosis patients were recruited for several other
studies. All medical staff is regularly informed about the
study, and posters with inclusion criteria and the phone
number of the study team were distributed.
Randomization
The randomization list was prepared in advance by the
statistician, stratified by site (Ifakara and Mwananya-
mala) and HIV status (positive or negative) with
randomly-varying block sizes. Patient allocation was
done in a 1:1 ratio to the intervention or control group.
The sequence was concealed by using envelopes pre-
pared by an independent person, based on the list pre-
pared by the statistician. The envelopes are opaque and
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sealed, labelled only with the stratification information
and a sequential number. Inside the envelope is a piece
of paper confirming the stratification information and
sequential number, and indicating the group allocation.
The envelopes are stored securely. Checks are performed
intermittently during enrolment to ensure that the
randomization sequence is being respected.
Allocation of patients to the intervention or control
group is done by the study clinical officers at each study
site, after history taking, physical examination, collection
of blood, urine and sputum for laboratory and microbio-
logical examinations, chest X-ray, HIV testing, and in-
formed consent. Based on the stratification of the
patients (i.e site and HIV status), the study clinical offi-
cers take the next sequentially numbered envelope. They
verify the information inside the envelope, and store the
allocation paper in the patient file for source document
verification if necessary.
Sample size
Assumptions for the sample size calculation were based
on data from the literature [1, 3, 6] and preliminary ana-
lysis of our observational study [9] (Table S2). Based on
these assumptions, 73 and 85% of patients in the control
and intervention groups, respectively, would be correctly
managed. For a power of 95% with a two-sided alpha of
0.05, this yields a sample size of 592 patients. Assuming
a lost to follow-up of 10%, 650 patients are required.
Data collection and management
All data are managed using Epidata (http://www.epidata.
dk/). Data are stored on a local computer. Data extrac-
tion is done daily and stored on a secured cloud storage
service accessible only by study team members through
a user name-password authentication. Since clinical,
microbiological and sonographic findings are crucial for
the decision to treat or not to treat a patient according
to the protocol, these findings are accessible to the
members of the study group. Information about results
of microbiological data are given to the treating physi-
cians of the patients in the control group. Direct access
to source documents is permitted for purposes of moni-
toring and inspections. Only investigators and the moni-
toring team have access to the dataset. All data are
checked and verified by the responsible investigators.
Statistical analyses
Analyses and reporting will follow CONSORT guidelines
(http://www.consort-statement.org/consort-2010) fol-
lowing intention to treat principles. Enrolment, random-
isation and follow-up will be described using a
flowchart. Baseline characteristics and outcomes will be
described by group using frequencies and percentages
for categorical variables and medians and interquartile
ranges for continuous outcomes. The primary outcome
will be compared between groups using logistic regres-
sion, reporting odds ratios with 95% confidence inter-
vals. We will adjust for the stratification variables [23],
and in sensitivity analyses for other baseline factors with
imbalances between groups (by visual inspection, with
no formal testing performed across groups) [24] or asso-
ciated with missing primary outcome data [25]. We will
assess effect modification of the primary outcome separ-
ately by HIV status and site, by using similar methods as
for the primary outcome and an interaction between
group and HIV status or site, respectively. Analyses of
the categorical secondary and safety outcomes will fol-
low similar methods as for the primary outcome, and
with proportional hazards models for the time to death
outcome if there are sufficient numbers of events. Inter-
rater reliability of eFASH findings between the sonogra-
pher and the independent reviewer will be evaluated. A
full statistical analysis plan will be developed.
Monitoring and auditing
Monitoring is done by independent members of the Ifa-
kara Health Institute. Monitoring is done at the begin-
ning of the study, after 1 year, and at the end of the
study. Health hazard of trial interventions that require
measures are reported to the sponsor-investigator, to the
study monitoring board, and to the local ethics commit-
tee. No interim analysis requiring a data monitoring
committee is planned.
Discussion
In 2018 an estimated 10 million new tuberculosis cases
occurred worldwide, and 1.45 million people died of the
disease [26]. Clinical symptoms can be sensitive, but not
specific for tuberculosis [27]. Moreover, in HIV positive
people on antiretroviral therapy, the absence of cough,
fever, night sweats, or weight loss does not exclude tu-
berculosis, because of the low sensitivity of these symp-
toms in this group of patients [28]. Microbiological
testing as the gold-standard remains challenging, with
severely ill patients and patients with extrapulmonary tu-
berculosis who are often unable to expectorate sputum.
Invasive sampling to acquire material for microbiology is
mostly not available [29]. Furthermore, a strategy relying
on spontaneously expectorated sputum is inadequate in
about one third of tuberculosis cases [30]. Moreover, pa-
tients with tuberculosis and HIV often have low bacillary
loads in sputum and other body cavity fluids, which re-
duces further the sensitivity of culture and Xpert MTB/
RIF® assay [31]. Therefore, patients are often empirically
treated despite negative microbiological tests [6]. Over-
treatment of patients who do not have tuberculosis gen-
erates unnecessary costs, exposes patients to potentially
toxic drugs, and might delay the diagnosis of the real
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cause of the disease. To our knowledge, this is the first
randomized controlled trial to assess whether sonog-
raphy, combined with chest X-ray and established
microbiological tests, can increase the proportion of cor-
rectly managed patients with clinically suspected extra-
pulmonary tuberculosis.
This trial has some limitations: First, we cannot pre-
vent doctors of patients in the control group from using
sonography as part of routine care (not according
eFASH protocol), which might reduce the real difference
in outcomes between the groups. Second, the study is
not blinded. However, results will reflect real life scenar-
ios. Third, according to our experience in the observa-
tional study [9], loss to follow-up is a frequent challenge
especially in the rural setting. We have attempted to ad-
dress this through increasing our sample size to allow
for some loss to follow-up. Fourth, this study is done in
an environment with high tuberculosis prevalence, and
findings cannot be transferred to low prevalence
settings.
In conclusion, this study is the first randomized con-
trolled trial investigating ultrasound in the management
of extrapulmonary tuberculosis. We hypothesize that
ultrasound, added to other tests, will increase the pro-
portion of correctly-managed patients, and therefore re-
duce overtreatment with anti-tuberculosis drugs.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-020-05073-9.
Additional file 1: Table S1. Study Schedule and Milestones. *Dates as
planned initially. Table S2. Assumptions for sample size calculation.
Shaded cells show those with correct management. TB=tuberculosis.
*Based on the treatment decision made within the first 48 hours after
primary evaluation.
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